Business Description
Regen BioPharma Inc
NAICS : 325414
SIC : 2834
ISIN : US75886M4096
Share Class Description:
RGBPP.PFD: Non Cum Pfd Registered Shs Series -A-Total Employee Number:
1Description
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -20.61 | |||||
Debt-to-Equity | -0.18 | |||||
Debt-to-EBITDA | -1.9 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -146.92 | |||||
Beneish M-Score | -13.01 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.9 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year FCF Growth Rate | 45.2 | |||||
3-Year Book Growth Rate | 49 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.79 | |||||
9-Day RSI | 52.33 | |||||
14-Day RSI | 52.08 | |||||
3-1 Month Momentum % | 106.25 | |||||
6-1 Month Momentum % | -89.85 | |||||
12-1 Month Momentum % | -89.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.05 | |||||
Days Sales Outstanding | 327.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.4 | |||||
Shareholder Yield % | -467.64 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -368.64 | |||||
Net Margin % | -302.97 | |||||
EBITDA Margin % | -214.41 | |||||
ROA % | -314.15 | |||||
ROIC % | -20.14 | |||||
3-Year ROIIC % | -0.05 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.04 | |||||
EV-to-EBIT | -2.13 | |||||
EV-to-EBITDA | -2.13 | |||||
EV-to-Revenue | 4.56 | |||||
EV-to-FCF | -2.26 | |||||
Earnings Yield (Greenblatt) % | -46.95 | |||||
FCF Yield % | -467.65 |
GF Valueâ„¢
Regen BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regen BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-08-11 | In 44 days | ||
| General meeting for 2025 | 2026-06-30 | In 2 days | ||
| Second quarter earnings results for 2026 | 2026-05-14 | 0.00 (-45.90%) | ||
| First quarter earnings results for 2026 | 2026-02-13 | 0.00 (-27.50%) | ||
| 2:1 Stock Split | 2026-02-10 | 0.01 (+82.12%) | ||
| Annual report for 2025 | 2025-12-30 | 0.03 (+92.59%) | ||
| Emerging Growth Conference 88 | 2025-12-10 12:00 | 0.04 (+3.00%) | ||
| The Emerging Growth Conference | 2025-09-24 16:25 | 0.02 (-30.64%) | ||
| Third quarter earnings results for 2025 | 2025-08-11 | 0.03 (-25.00%) | ||
| Emerging Growth Conference 83 | 2025-06-18 15:25 | 0.03 (+9.45%) |
Show
Entries
Guru Commentaries on OTCPK:RGBPP.PFD
No articles.
Press Release
Articles on Regen BioPharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers